Drug-induced liver injury network causality assessment: Criteria and experience in the United States

International Journal of Molecular Sciences

Volumn 17, Issue 2, 2016, Pages

  Hayashi, Paul H ^a  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Causality; Diagnosis; Expert opinion; Hepatotoxicity

Indexed keywords

PARACETAMOL;

CLINICAL ASSESSMENT; COMORBIDITY; DIABETES MELLITUS; DIET SUPPLEMENTATION; DISEASE REGISTRY; GASTROINTESTINAL DISEASE; GEOGRAPHIC DISTRIBUTION; HUMAN; INFORMATION PROCESSING; KIDNEY DISEASE; LIVER TOXICITY; PSYCHOMETRY; REVIEW; TOXIC HEPATITIS; UNITED STATES; CHEMICAL AND DRUG INDUCED LIVER INJURY; CONSENSUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXPERT WITNESS;

CHEMICAL AND DRUG INDUCED LIVER INJURY; CONSENSUS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EXPERT TESTIMONY; HUMANS; PSYCHOMETRICS; UNITED STATES;

EID: 84957565273     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17020201     Document Type: Review

References (30)

1. Hoofnagle, J.H. Drug-induced liver injury network (DILIN). Hepatology 2004, 40, 773. [CrossRef] [PubMed]
2. Fontana, R.J.; Watkins, P.B.; Bonkovsky, H.L.; Chalasani, N.; Davern, T.; Serrano, J.; Rochon, J. Drug-Induced Liver Injury Network (DILIN) prospective study: Rationale, design and conduct. Drug Saf. 2009, 32, 55-68. [CrossRef] [PubMed]
3. Agarwal, V.K.; McHutchison, J.G.; Hoofnagle, J.H. Important elements for the diagnosis of drug-induced liver injury. Clin. Gastroenterol. Hepatol. 2010, 8, 463-470. [CrossRef] [PubMed]
4. Davern, T.J.; Chalasani, N.; Fontana, R.J.; Hayashi, P.H.; Protiva, P.; Kleiner, D.E.; Engle, R.E.; Nguyen, H.; Emerson, S.U.; Purcell, R.H. Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011, 141, 1665-1672. [CrossRef] [PubMed]
5. Dalton, H.R.; Fellows, H.J.; Stableforth, W.; Joseph, M.; Thurairajah, P.H.; Warshow, U.; Hazeldine, S.; Remnarace, R.; Ijaz, S.; Hussaini, S.H. The role of hepatitis E virus testing in drug-induced liver injury. Aliment. Pharmacol. Ther. 2007, 26, 1429-1435. [CrossRef] [PubMed]
6. Rockey, D.C.; Seeff, L.B.; Rochon, J.; Freston, J.; Chalasani, N.; Bonacini, M.; Fontana, R.J.; Hayashi, P.H. Causality assessment in drug-induced liver injury using a structured expert opinion process: Comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010, 51, 2117-2126. [CrossRef] [PubMed]
7. Maria, V.A.; Victorino, R.M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997, 26, 664-669. [CrossRef] [PubMed]
8. Lucena, M.I.; Camargo, R.; Andrade, R.J.; Perez-Sanchez, C.J. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001, 33, 123-130. [CrossRef] [PubMed]
9. Arimone, Y.; Begaud, B.; Miremont-Salame, G.; Fourrier-Reglat, A.; Moore, N.; Molimard, M.; Haramburu, F. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur. J. Clin. Pharmacol. 2005, 61, 169-173. [CrossRef] [PubMed]
10. Arimone, Y.; Miremont-Salame, G.; Haramburu, F.; Molimard, M.; Moore, N.; Fourrier-Reglat, A.; Begaud, B. Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions. Br. J. Clin. Pharmacol. 2007, 64, 482-488. [CrossRef] [PubMed]
11. Hayashi, P.H.; Barnhart, H.X.; Fontana, R.J.; Chalasani, N.; Davern, T.J.; Talwalkar, J.A.; Reddy, K.R.; Stolz, A.A.; Hoofnagle, J.H.; Rockey, D.C. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int. 2015, 35, 1623-1632. [CrossRef] [PubMed]
12. Danan, G.; Benichou, C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J. Clin. Epidemiol. 1993, 46, 1323-1330. [CrossRef]
13. Daly, A.K.; Aithal, G.P.; Leathart, J.B.; Swainsbury, R.A.; Dang, T.S.; Day, C.P. Genetic susceptibility to diclofenac-induced hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 2007, 132, 272-281. [CrossRef] [PubMed]
14. Huang, Y.S.; Chern, H.D.; Su, W.J.; Wu, J.C.; Chang, S.C.; Chiang, C.H.; Chang, F.Y.; Lee, S.D. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology 2003, 37, 924-930. [CrossRef] [PubMed]
15. Lucena, M.I.; Andrade, R.J.; Martinez, C.; Ulzurrun, E.; Garcia-Martin, E.; Borraz, Y.; Fernandez, M.C.; Romero-Gomez, M.; Castiella, A.; Planas, R. Glutathione S-transferase m1 and t1 null genotypes increase susceptibility to idiosyncratic drug-induced liver injury. Hepatology 2008, 48, 588-596. [CrossRef] [PubMed]
16. Ritchie, M.D.; Haas, D.W.; Motsinger, A.A.; Donahue, J.P.; Erdem, H.; Raffanti, S.; Rebeiro, P.; George, A.L.; Kim, R.B.; Haines, J.L. Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity. Clin. Infect. Dis. 2006, 43, 779-782. [CrossRef] [PubMed]
17. Watanabe, I.; Tomita, A.; Shimizu, M.; Sugawara, M.; Yasumo, H.; Koishi, R.; Takahashi, T.; Miyoshi, K.; Nakamura, K.; Izumi, T. Astudy to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther. 2003, 73, 435-455. [CrossRef]
18. Donaldson, P.T.; Bhatnagar, P.; Graham, J.; Henderson, J.; Leathart, J.B.; Pirmohamed, M.; Bernal, W.; Aithal, G.P.; Day, C.P.; Daly, A.K. Flucloxacillin-induced liver injury: The extended MHC 57.1 haplotype as a major risk factor. Hepatology 2008, 48, 396A.
19. Lucena, M.I.; Molokhia, M.; Shen, Y.; Urban, T.J.; Aithal, G.P.; Andrade, R.J.; Day, C.P.; Ruiz-Cabello, F.; Donaldson, P.T.; Stephens, C. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141, 338-347. [CrossRef] [PubMed]
20. Phillips, E.; Bartlett, J.A.; Sanne, I.; Lederman, M.M.; Hinkle, J.; Rousseau, F.; Dunn, D.; Pavlos, R.; James, I.; Mallal, S.A. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J. Acquir. Immune Defic. Syndr. 2013, 62, e55-e57. [CrossRef] [PubMed]
21. Singer, J.B.; Lewitzky, S.; Leroy, E.; Yang, F.; Zhao, X.; Klickstein, L.; Wright, T.M.; Meyer, J.; Paulding, C.A. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 2010, 42, 711-714. [CrossRef] [PubMed]
22. Spraggs, C.F.; Budde, L.R.; Briley, L.P.; Bing, N.; Cox, C.J.; King, K.S.; Whittaker, J.C.; Mooser, V.E.; Preston, A.J.; Stein, S.H. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J. Clin. Oncol. 2011, 29, 667-673. [CrossRef] [PubMed]
23. Hirata, K.; Takagi, H.; Yamamoto, M.; Matsumoto, T.; Nishiya, T.; Mori, K.; Shimizu, S.; Masumoto, H.; Okutani, Y. Ticlopidine-induced hepatotoxicity is associated with specific human leukocyte antigen genomic subtypes in Japanese patients: A preliminary case-control study. Pharm. J. 2008, 8, 29-33. [CrossRef] [PubMed]
24. Kleiner, D.E.; Chalasani, N.P.; Lee, W.M.; Fontana, R.J.; Bonkovsky, H.L.; Watkins, P.B.; Hayashi, P.H.; Davern, T.J.; Navarro, V.; Reddy, R. Hepatic histological findings in suspected drug-induced liver injury: Systematic evaluation and clinical associations. Hepatology 2013, 59, 661-670. [CrossRef] [PubMed]
25. Teschke, R.; Eickhoff, A.; Schulze, J. Drug- and herb-induced liver injury in clinical and translational hepatology: Causality assessment methods, quo vadis? J. Clin. Transl. Hepatol. 2013, 1, 59-74. [CrossRef] [PubMed]
26. Navarro, V.J.; Barnhart, H.; Bonkovsky, H.L.; Davern, T.; Fontana, R.J.; Grant, L.; Reddy, K.R.; Seeff, L.B.; Serrano, J.; Sherker, A.H. Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network. Hepatology 2014, 60, 1399-1408. [CrossRef] [PubMed]
27. Navarro, V.J.; Lucena, M.I. Hepatotoxicity induced by herbal and dietary supplements. Semin. Liver Dis. 2014, 34, 172-193. [PubMed]
28. Fleshner, N.; Harvey, M.; Adomat, H.; Wood, C.; Eberding, A.; Hersey, K.; Guns, E. Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type 5 inhibitors. J. Urol. 2005, 174, 636-641. [CrossRef] [PubMed]
29. Saper, R.B.; Phillips, R.S.; Sehgal, A.; Khouri, N.; Davis, R.B.; Paquin, J.; Thuppil, V.; Kales, S.N. Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold via the Internet. JAMA 2008, 300, 915-923. [CrossRef] [PubMed]
30. Rockey, D.C.; Hayashi, P.H.; Tillmann, H.; Gu, J.; Ghabril, M.; Ahmad, J.; Stolz, A.; Fontana, R.J.; Hoofnagle, J.H. Liver disorders that can masquerade as drug-induced liver injury. Hepatology 2015, 62, 1149A. [CrossRef]